[1] Thomas DA,Kantarjian H,Smith TL,et al.Primary refractory and relapsed adult acute lymphoblastic leukemia:characteristics,treatment results and prognosis with salvage therapy [J].Cancer,1999,86(7):1216-30. [2] Mengarelli A,Iori AP,Guglielmi C,et al.Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia [J].Haematologica,2002,87(2):52-8. [3] 第二届全国难治性白血病研讨会.关于难治性急性白血病诊断标准的建议(草案)[J].白血病(Leukemia),2000,9(1):63-84. [4] 刘启发,孙竞,张钰,等.环孢素A+氨甲喋呤+霉酚酸酯+抗胸腺球蛋白四联方案预防无关供体造血干细胞移植中的移植物抗宿主病[J] 第一军医大学学报,2003,23(11):1143-5.Liu QF,Sun J,Zhang Y,et al.Quadruple therapy with CsA,MTX,MMF and ATG for preventing graft-versus-host disease in unrelated donor hematopoietic stem cell transplantation [J].J First Mil Med Univ/Di Yi Jun Yi Da Xue Xue Bao,2003,23(11):1143-5. [5] Bearman SI,Applbaum FR,Buckner CD,et al.Regimen related toxicity in patients undergoing bone marrow transplantation [J].J Clin Oncol,1988,6(11):1562-7. [6] Demirer T,Buckner CD,Appelbaum FR,et al.Busulfan,cyclophosphamide and franctionated total irradiation for allogeneic marrow transplantation in advanced acute and chronic myelogenous leukemia:phase I dose escalation of busulfan based on targeted plasma levels[J].Bone Marrow Transplant,1996,17(5):341-6. [7] Singhal S,Powles R,Henslee-Downey PJ,et al.Allogeneic transplantation from HLA-matched sibling or partially HLAmismatched related donors for primary refractory acute leukemia[J].Bone Marrow Transplant,2002,29(4):291-5. [8] Kolb HJ,Schmid C,Barrett AJ,et al.Graft-versus-leukemia reactions in allogeneic chimeras[J].Blood,2004,103(3):767-76. [9] Kolb HJ,Schattenberg A,Goldman JM,et al.Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients.European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia[J].Blood,1995,86(9):2041-50. |